Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • ID: 3957693
  • Report
  • Region: Global
  • 192 Pages
  • GBI Research
1 of 5
Cardiovascular Disease Market Set to Grow Very Slowly to $146.4 Billion by 2022

FEATURED COMPANIES

  • AstraZeneca
  • Bayer
  • Daiichi Sankyo
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

Within cardiovascular disease there are a number of blockbuster products that have recently gone off-patent or are expected to in the coming years. Many of these drugs belong to key players in the cardiovascular market, and constitute a large proportion of their revenue within cardiovascular disease. For example, the current market leader, AstraZeneca’s Crestor (rosuvastatin), generated around $7 Billion in 2011. However, revenues are expected to drop sharply following the expiration of its patent on July 8, 2016 - total annual revenues are expected to be around $1.3 Billion in 2022.

Novartis’ heart failure drug Entresto (valsartan plus sacubitril in a 1:1 mixture by molecule count) was introduced to market in July 2015, and its revenues are expected to increase dramatically during the forecast period. Entresto is a combination drug indicated for the treatment of heart failure with reduced left ventricular ejection fraction. It performed well in clinical trials, and therefore represents a better alternative to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) for the treatment of heart failure. The efficacy shown in clinical trials, coupled with the high cost, which amounts to over $4,500 annually per patient, contributes to a very high revenue forecast. Sales for Entresto are expected to reach $5.7 Billion by 2022.

There are 406 antithrombotic products within the pipeline, compared with just 229 for dyslipidemia and 197 for hypertension. This suggests that key players within the cardiovascular disease market are focusing on creating drugs for thrombotic events, and may ultimately result in more thrombotic event drugs entering the market in comparison to anti-hypertensive or anti-dyslipidemia drugs.

The report “Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth” provides an overview of the cardiovascular disease marketed products landscape, including product profiles of key marketed products.

In depth, this report provides the following:
  • It analyzes the cardiovascular disease pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: Acute coronary syndrome, hypertension, dyslipidemia and stroke.
  • Provides forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in cardiovascular disease, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Aanalyses trends in co-development and licensing deals, relating to cardiovascular disease products. Some of the most prominent deals are discussed in detail.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Bayer
  • Daiichi Sankyo
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology, Pathophysiology, Comorbidities and Complications
2.3.1 Hypertension
2.3.2 Dyslipidemia
2.3.3 Thrombotic events
2.4 Diagnosis
2.4.1 Hypertension
2.4.2 Dyslipidemia
2.4.3 Thrombotic events
2.5 Prognosis
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.6.1 Hypertension
2.6.2 Dyslipidemia
2.6.3 Thrombotic events
2.7 Treatment
2.7.1 Thiazide Diuretics
2.7.2 Angiotensin Converting Enzyme Inhibitors
2.7.3 Angiotensin Receptor Blockers
2.7.4 Calcium Channel Blockers
2.7.5 Statins
2.7.6 Anticoagulants
2.7.7 Antiplatelet Drugs
2.7.8 Beta-adrenoceptor antagonists (Beta blockers)
2.7.9 Other Drugs

3 Key Marketed Products
3.1 Overview
3.2 Crestor (rosuvastatin) - AstraZeneca
3.3 Zetia (ezetimibe) - Merck & Co
3.4 Lipitor (atorvastatin) - Pfizer
3.5 Praluent (alirocumab) - Sanofi
3.6 Xarelto (rivaroxaban) - Bayer
3.7 Eliquis (apixaban) - Bristol-Myers Squibb and Pfizer
3.8 Plavix (clopidogrel) - Sanofi
3.9 Brilinta (ticagrelor) - AstraZeneca
3.10 Entresto (valsartan plus sacubitril) - Novartis
3.11 Benicar (olmesartan medoxomil) - Daiichi Sankyo
3.12 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Conclusion

5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Coagulation Cascade
5.3.2 P2Y12 Receptors
5.3.3 Beta 1 Adrenergic Receptors
5.3.4 PCSK9 Inhibitors
5.3.5 HMG-CoA Reductase Inhibitors (statins)
5.3.6 Renin angiotensin system (RAS)
5.3.7 Revenue and Market Share Analysis by Company
5.3.8 Assessment of Key Pipeline Products

6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Licensing Deals Valued Above $200m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Co-development Deals Valued Above $100m

8 Appendix
8.1 References
8.2 Tables of All Pipeline Products
8.3 Table of Epidemiology Forecast
8.4 Abbreviations
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape

List of Tables
Table 1: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category
Table 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, 2016
Table 3: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Crestor, 2016
Table 4: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Zetia, 2016
Table 5: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Lipitor, 2016
Table 6: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Praluent, 2016
Table 7: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Xarelto, 2016
Table 8: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Eliquis, 2016
Table 9: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Plavix, 2016
Table 10: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Brilinta, 2016
Table 11: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Entresto, 2016
Table 12: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Benicar, 2016
Table 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
Table 14: Cardiovascular Disease Therapeutics Market, Global, Usage of Generics Across Key Indications, 2015
Table 15: Cardiovascular Disease Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022
Table 16: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016
Table 17: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016
Table 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Discovery, 2016
Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Preclinical, 2016
Table 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2016
Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase I, 2016
Table 22: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase II, 2016
Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase III, 2016
Table 24: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016
Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Unknown, 2016
Table 26: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Hypertension, 2015-2022
Table 27: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Dyslipidemia, 2015-2022
Table 28: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Acute Coronary Syndrome, 2015-2022
Table 29: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Ischemic Stroke, 2015-2022
Table 30: Cardiovascular Disease Therapeutics Market, Incident Cases for Venous Thromboembolism, 2015-2022
Table 31: Abbreviations

List of Figures
Figure 1: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Hypertension, 2015-2022
Figure 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Dyslipidemia, 2015-2022
Figure 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Acute Coronary Syndrome, Ischemic Stroke and Venous Thromboembolism, 2015-2022
Figure 4: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Crestor ($bn), 2006-2022
Figure 5: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Zetia ($bn), 2006-2022
Figure 6: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Lipitor ($bn), 2006-2022
Figure 7: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Praluent ($bn), 2006-2022
Figure 8: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Xarelto ($bn), 2006-2022
Figure 9: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Eliquis ($bn), 2006-2022
Figure 10: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Plavix ($bn), 2006-2022
Figure 11: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Brilinta ($bn), 2006-2022
Figure 12: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Entresto ($bn), 2006-2022
Figure 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Benicar ($bn), 2006-2022
Figure 14: Cardiovascular Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Cardiovascular Diseases by Stage of Development, Molecule Type and Program Type, 2016
Figure 16: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2016
Figure 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2016
Figure 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2016
Figure 21: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 22: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 23: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 24: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 25: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 26: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 27: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 28: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 29: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 30: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 31: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 32: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 33: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 34: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 35: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 36: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 37: Cardiovascular Disease Therapeutics Market, Global, Market Size ($bn), 2015-2022
Figure 38: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
Figure 39: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2015-2022
Figure 40: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2015-2022
Figure 41: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2015-2022
Figure 42: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($m), 2015-2022
Figure 43: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2015-2022
Figure 44: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2015-2022
Figure 45: Cardiovascular Disease Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 46: Cardiovascular Disease Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 47: Cardiovascular Disease Therapeutics Market, Global, Revenues by Product Type, 2015-2022
Figure 48: Cardiovascular Disease Therapeutics Market, Global, Sanofi Annual Revenue Forecast ($bn), 2015-2022
Figure 49: Cardiovascular Disease Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015-2022
Figure 50: Cardiovascular Disease Therapeutics Market, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022
Figure 51: Cardiovascular Disease Therapeutics Market, Global, Bayer Annual Revenue Forecast ($bn), 2015-2022
Figure 52: Cardiovascular Disease Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022
Figure 53: Cardiovascular Disease Therapeutics Market, Global, Merck Annual Revenue Forecast ($bn), 2015-2022
Figure 54: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Bococizumab ($m), 2018-2022
Figure 55: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Betrixaban ($m), 2017-2022
Figure 56: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Anacetrapib ($m), 2018-2022
Figure 57: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Volanesorsen ($m), 2017-2022
Figure 58: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Vericiguat ($m), 2018-2022
Figure 59: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for ETC-1002 ($m), 2018-2022
Figure 60: Cardiovascular Disease Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 61: Cardiovascular Disease Therapeutics Market, Global, Companies by Type, 2016
Figure 62: Cardiovascular Disease Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2016
Figure 63: Cardiovascular Disease Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2015-2022
Figure 64: Cardiovascular Disease Therapeutics Market, Global, Top Six Companies, Proportion of Total Company Revenue Attributed to Cardiovascular Disease ($bn), 2015-2022
Figure 65: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016
Figure 66: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Indication, 2006-2016
Figure 67: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 68: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
Figure 69: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016
Figure 70: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
Figure 71: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca 
  • Bayer
  • Bristol-Myers Squibb and Pfizer
  • Daiichi Sankyo
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi 
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll